Cagrilintide;Cargliptin;Caglitide;Cagrilintide acetate;Cagrilintide peptide

1.Description

Cagrilintide, research code AM833 / AT42613, CAS No. 1415456‑99‑3, is a long‑acting synthetic amylin analogue developed by the Danish pharmaceutical company Novo Nordisk. It belongs to the peptide drugs of amylin receptor / calcitonin receptor agonist class.
Chemical Information.

2.Function

Cagrilintide exerts its main functions by mimicking the physiological effects of the human endogenous hormone amylin, as follows:
1. Central‑mediated appetite suppression and enhanced satiety
Cagrilintide activates amylin receptors in the area postrema of the medulla oblongata and the hypothalamus within the central nervous system. It directly regulates the appetite‑control center to reduce hunger and increase satiety, thereby lowering spontaneous food intake. This represents its core mechanism of action.

2. Delayed gastric emptying
It slows gastric emptying, prolongs post‑prandial satiety duration, reduces eating frequency and single‑meal food intake, and mitigates post‑prandial blood glucose fluctuations.

3. Significant body weight reduction
Monotherapy: In the REDEFINE 1 Phase III trial, monotherapy with 2.4 mg cagrilintide achieved approximately 12% body weight loss.
Combination therapy (CagriSema): Combined with semaglutide, its weight‑loss effect is greatly enhanced, reaching over 20%.

4. Improved glycemic control
It reduces post‑prandial blood glucose fluctuations via delayed gastric emptying and improves insulin sensitivity through weight loss, leading to substantial reductions in HbA1c levels among patients with type 2 diabetes mellitus.

3.Application fields

1. Obesity and Weight Management (Core Indication)
The primary application of cagrilintide (especially the CagriSema fixed‑dose combination) is long‑term weight management in adults with obesity or overweight accompanied by weight‑related comorbidities. Trials within the REDEFINE clinical program have demonstrated its remarkable weight‑loss efficacy of over 20%, placing it among the first‑line weight‑loss pharmacotherapies currently available.

2. Type 2 Diabetes Mellitus
Trials from the REIMAGINE clinical program have proven that CagriSema delivers dual benefits of marked glycemic reduction (lowered HbA1c) and weight loss in patients with type 2 diabetes mellitus, with superior outcomes compared with semaglutide monotherapy. It is indicated for patients with type 2 diabetes mellitus who require concurrent glycemic and weight control.

3. Metabolic Syndrome
By reducing body weight, improving insulin sensitivity, and regulating blood glucose and blood lipids, cagrilintide can ameliorate multiple markers of metabolic syndrome, including waist circumference, blood pressure, triglycerides, and HDL‑cholesterol.

4. Potential Expanded Indications
Reduction of cardiometabolic risk: Weight loss and metabolic improvements may confer cardiovascular benefits, and relevant outcome studies are ongoing.
MASH (Metabolic‑Associated Steatohepatitis): It may possess therapeutic potential for MASH via weight reduction and mitigation of hepatic fat accumulation.
Obstructive Sleep Apnea (OSA): Weight loss can alleviate OSA symptoms.

4. Packing & Shipping

Generally, the Bergenin  will be packed in two plastic bags and one foil bag, and then a fiber drum for 25kg.